



The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
June 13, 2023

Therapeutic Class	Drug Name	DURB Recommendation*
Antidepressants, Other		
	<i>Auvelity (Oral) Tablet</i>	NP/PA
Hemophilia Treatment		
	<i>Hemgenix (Intravenous) Suspension</i>	PADL with PA
ALS Agents		
	<i>Relyvrio (Oral) Suspension</i>	NP/PA
Colony Stimulating Factors		
	<i>Rolvedon (Subcutaneous) Injection</i>	NP/PA (PDL and PADL)
Biologic Immunomodulators		
	<i>Sotyktu (Oral) Tablet</i>	NP/PA
β-thalassemia Agents		
	<i>Zynteglo (Intravenous) Suspension</i>	Tabled

*All recommendations apply to the PDL unless explicitly stated otherwise; DURB=Drug Utilization Review Board; P=preferred; NP=non-preferred; PA=prior authorization; PDL=Preferred Drug List; PADL=Providers' Administered Drug List